FateControl™ technology incorporated in MYTX-011 enables increased delivery of ADC payload to tumors in a NSCLC xenograft model with moderate cMET expression
MYTX-011 is efficacious against cMET-expressing xenograft models derived from multiple solid tumor types including gastric, esophageal, and head and neck cancers
WALTHAM, MA, USA I April 08, 2024 I Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, presented preclinical data from MYTX-011, its investigational cMET-targeting ADC, at the American Association for Cancer Research (AACR) Annual Meeting.
“Patients with tumors expressing low-to-moderate levels of cMET have not been able to fully benefit from ADC therapies available today, and we continue to be encouraged by the progress made with MYTX-011,” said Brian Fiske, Ph.D., Chief Scientific Officer and Co-founder of Mythic. “We previously demonstrated that MYTX-011 drives increased internalization and cytotoxicity in tumor cells expressing moderate cMET levels compared to a matched parent ADC in vitro. This new study adds to our excitement by illustrating how our FateControl™ technology, incorporated into MYTX-011, enables increased delivery of the ADC’s cytotoxic payload to tumors with moderate cMET expression in vivo. We’re also pleased to present data that highlight the potential of MYTX-011 as a therapeutic candidate for treating multiple types of solid tumors that express cMET.”
MYTX-011 is an investigational, pH-sensitive, vcMMAE-based ADC that is designed to benefit not only patients whose tumors express high levels of cMET, but also a broader set of patients whose tumors express low to moderate levels of cMET. MYTX-011 is engineered to rapidly dissociate from cMET only at the acidic pH of endolysosomes.
In studies presented at AACR, the pH-engineered antibody component of MYTX-011 demonstrated markedly increased accumulation in cancer cells expressing high, moderate or low cMET levels compared to its matched non-engineered parent antibody. Consistent with this finding, MYTX-011 demonstrated broader and more potent cMET-dependent cytotoxicity across a panel of cancer cell lines compared to a matched parent ADC. Moreover, in mice bearing NSCLC xenograft tumors with moderate cMET expression, MYTX-011 treatment delivered increased levels of MMAE payload to tumors in vivo as compared to the parent ADC. MYTX-011 was shown to be highly active in cMET+ xenograft models derived from gastric, esophageal and head and neck cancers. Together, these findings provide preclinical proof-of-concept of the potential of MYTX-011 as a therapeutic candidate for treating a broader range of cMET-expressing malignancies.
About MYTX-011
MYTX-011, an investigational cMET-targeting ADC, leverages Mythic’s innovative FateControl™ technology, which allows antibody-drug conjugates (ADCs) to actively navigate inside of cells, potentially increasing delivery of anti-cancer agents to tumor cells with less impact on healthy cells. This breakthrough approach takes the next step beyond linker-payload technologies and is designed to improve ADC efficacy against a broad set of molecular targets and patient profiles. MYTX-011 is currently being evaluated in the Phase 1 KisMET-01 clinical trial, a first-in-human, open-label, multi-center, dose escalation and dose expansion study enrolling patients with locally advanced, recurrent or metastatic NSCLC (NCT05652868).
About Mythic Therapeutics
Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The Company’s FateControl™ technology aims to enhance ADC uptake in targeted tissues by manipulating the fate of the ADC within the cell, thereby expanding the diseases and patient profiles that could be treated with Mythic’s ADCs. The company’s major investors include Venrock, Viking Global Investors, and First Round Capital.
For more information, visit: www.mythictx.com and follow on LinkedIn.
SOURCE: Mythic Therapeutics
Post Views: 513
FateControl™ technology incorporated in MYTX-011 enables increased delivery of ADC payload to tumors in a NSCLC xenograft model with moderate cMET expression
MYTX-011 is efficacious against cMET-expressing xenograft models derived from multiple solid tumor types including gastric, esophageal, and head and neck cancers
WALTHAM, MA, USA I April 08, 2024 I Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, presented preclinical data from MYTX-011, its investigational cMET-targeting ADC, at the American Association for Cancer Research (AACR) Annual Meeting.
“Patients with tumors expressing low-to-moderate levels of cMET have not been able to fully benefit from ADC therapies available today, and we continue to be encouraged by the progress made with MYTX-011,” said Brian Fiske, Ph.D., Chief Scientific Officer and Co-founder of Mythic. “We previously demonstrated that MYTX-011 drives increased internalization and cytotoxicity in tumor cells expressing moderate cMET levels compared to a matched parent ADC in vitro. This new study adds to our excitement by illustrating how our FateControl™ technology, incorporated into MYTX-011, enables increased delivery of the ADC’s cytotoxic payload to tumors with moderate cMET expression in vivo. We’re also pleased to present data that highlight the potential of MYTX-011 as a therapeutic candidate for treating multiple types of solid tumors that express cMET.”
MYTX-011 is an investigational, pH-sensitive, vcMMAE-based ADC that is designed to benefit not only patients whose tumors express high levels of cMET, but also a broader set of patients whose tumors express low to moderate levels of cMET. MYTX-011 is engineered to rapidly dissociate from cMET only at the acidic pH of endolysosomes.
In studies presented at AACR, the pH-engineered antibody component of MYTX-011 demonstrated markedly increased accumulation in cancer cells expressing high, moderate or low cMET levels compared to its matched non-engineered parent antibody. Consistent with this finding, MYTX-011 demonstrated broader and more potent cMET-dependent cytotoxicity across a panel of cancer cell lines compared to a matched parent ADC. Moreover, in mice bearing NSCLC xenograft tumors with moderate cMET expression, MYTX-011 treatment delivered increased levels of MMAE payload to tumors in vivo as compared to the parent ADC. MYTX-011 was shown to be highly active in cMET+ xenograft models derived from gastric, esophageal and head and neck cancers. Together, these findings provide preclinical proof-of-concept of the potential of MYTX-011 as a therapeutic candidate for treating a broader range of cMET-expressing malignancies.
About MYTX-011
MYTX-011, an investigational cMET-targeting ADC, leverages Mythic’s innovative FateControl™ technology, which allows antibody-drug conjugates (ADCs) to actively navigate inside of cells, potentially increasing delivery of anti-cancer agents to tumor cells with less impact on healthy cells. This breakthrough approach takes the next step beyond linker-payload technologies and is designed to improve ADC efficacy against a broad set of molecular targets and patient profiles. MYTX-011 is currently being evaluated in the Phase 1 KisMET-01 clinical trial, a first-in-human, open-label, multi-center, dose escalation and dose expansion study enrolling patients with locally advanced, recurrent or metastatic NSCLC (NCT05652868).
About Mythic Therapeutics
Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The Company’s FateControl™ technology aims to enhance ADC uptake in targeted tissues by manipulating the fate of the ADC within the cell, thereby expanding the diseases and patient profiles that could be treated with Mythic’s ADCs. The company’s major investors include Venrock, Viking Global Investors, and First Round Capital.
For more information, visit: www.mythictx.com and follow on LinkedIn.
SOURCE: Mythic Therapeutics
Post Views: 513
